RESOURCES
Jointly provided by Partners for Advancing Clinical Education (PACE) and Miller Medical Communications, LLC.
This activity is supported by an independent educational grant from Castle Biosciences.
© 2023 Miller Medical Communications, LLC.
Brent R. Moody, MDSkin Cancer Surgery Center
Nashville, Tennessee
Brent R. Moody, MD, is a Mohs surgeon from Nashville, Tennessee, who completed medical school at Emory University School of Medicine in Atlanta, Georgia, and progressed to full internal medicine and dermatology residencies at Washington University in St. Louis, St. Louis, Missouri. He then completed a comprehensive fellowship in Mohs surgery with Dr. George Hruza at the Laser and Dermatologic Surgery Center in St. Louis. Currently the vice president of the American College of Mohs Surgery and a member of the American Academy of Dermatology Board of Directors, he has been practicing in Nashville since 2003, where he has been using gene expression profiling (GEP) testing as part of his practice since 2019 and has tested more than 300 hundred tumors. Dr. Moody has become an expert in the use of GEP in the management of skin cancers.
Sancy A. Leachman, MD, PhD (Program Chair)Professor & Chair
Department of Dermatology
Oregon Health & Science University
Director of Melanoma Program
OHSU Knight Cancer Research Center
Portland, Oregon
Sancy A. Leachman, MD, PhD, is a physician-scientist who chairs the Department of Dermatology at Oregon Health & Science University (OHSU) and is the director of the Melanoma Research Program at the OHSU Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center. The inaugural recipient of the John D. Gray Endowed Chair in Melanoma Research and chair of the Southwest Oncology Group Melanoma Prevention Working Group, she is a dermatologist using basic science research and state-of-the-art technology to combat skin cancer.
Dr Leachman’s research examines the role of genetic predisposition and differential gene expression in the development of melanoma, with an emphasis on the familial melanoma syndrome. She is interested in prevention, early detection, and chemoprevention of melanoma, particularly in genetically predisposed melanoma families. Through her investigations, she is seeking to develop agents that will serve as diagnostic tools, prognostic indicators, or targeted agents for the prevention of melanoma.
Dr Leachman is passionate about fighting the “War on Melanoma” (an all-fronts effort to eliminate melanoma in Oregon) and has led the effort in building one of the largest national melanoma patient registries in the state. In line with the OHSU Knight Cancer Institute’s focus on the early detection of cancer, she and her team developed a mobile phone app, MoleMapper, which tracks moles and their change and growth over time. MoleMapper helps to gather data for melanoma research and, potentially, impact health outcomes in individuals at risk.
Prior to joining OHSU in 2013, Dr Leachman was director of the Melanoma and Cutaneous Oncology Program at Huntsman Cancer Institute at The University of Utah in Salt Lake City, a professor in the Department of Dermatology, and member of the Imaging, Diagnostics, and Therapeutics Program and the Cancer Control and Population Sciences Program.
Dr Leachman also worked on a DNA vaccination study to prevent and treat papillomavirus-induced squamous cell carcinoma at Yale University School of Medicine, New Haven, Connecticut. She was awarded the prestigious Doris Duke Clinical Scientist Development Award in 2000 and is currently an NIH R01- and Department of Defense-funded principal investigator.
Dr Leachman earned medical and doctorate degrees at the University of Texas Southwestern Medical School, Dallas, Texas. She served a residency at Yale-New Haven Hospital (dermatology) in New Haven, Connecticut, and completed a fellowship in cutaneous oncology at Yale University School of Medicine. She is certified by the American Board of Dermatology.
Sherrif F. Ibrahim, MD, PhDSherrif F. Ibrahim, MD, PhD, is a double board certified dermatologist and Mohs surgeon and a fellow of the American Academy of Dermatology and American College of Mohs Surgery. He is the founder of Rochester Dermatologic Surgery, Victor, New York, and an associate professor of dermatology at the University of Rochester Medical Center, Rochester, New York. He completed residency training at the University of Rochester followed by a fellowship in Mohs surgery, facial reconstruction, laser surgery, and cosmetic dermatology at the University of California, San Francisco.
He is passionate about the treatment of all types of skin cancer and is involved in the most cutting-edge aspects of care and research. He acts as a national key opinion leader for many therapeutic areas and helps bring these new advances to mainstream care. Dr Ibrahim publishes regularly in all major skin cancer-related journals, lectures nationally, and has performed more than 20,000 Mohs surgery cases.
Dr Ibrahim has been involved with gene expression profiling (GEP) testing in squamous cell carcinoma since its inception. He has served as principal investigator on the pivotal validation study that ultimately led to the approval of this test as well as several follow-up prospective studies currently under way. He continues to play a role in the integration of GEP testing across many aspects of skin cancer.
Laura K. Ferris, MD, PhDProfessor of Dermatology
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Laura Korb Ferris, MD, PhD, received her doctorate degree in immunology from Johns Hopkins School of Medicine, Baltimore, Maryland, and her medical degree from University of Maryland in College Park, Maryland. She completed her residency in dermatology and fellowship in cutaneous oncology at the University of Pittsburgh, in Pennsylvania. At present she is professor of dermatology at the University of Pittsburgh Medical Center (UPMC) Department of Dermatology, where she directs the departmental clinical trials unit as well as both the psoriasis and pigmented skin lesions clinics. She has been a principal investigator on more than 100 clinical trials of therapies and diagnostic tools in dermatology. She is also part of the University of Pittsburgh Hillman Cancer Center melanoma program. Her research is focused on strategies to improve melanoma early detection both through screening and the use of novel technologies. To that end, Dr Ferris has helped to develop a primary care-based skin cancer screening program at UPMC with the goal of helping to improve early melanoma detection and reducing melanoma mortality across western Pennsylvania, and to design a model that can be applied to health systems nationally.